# Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

> **NCT03996369** · PHASE3 · COMPLETED · sponsor: **Arena Pharmaceuticals** · enrollment: 354 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Etrasimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03996369
- **Lead sponsor:** Arena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-15
- **Primary completion:** 2021-12-07
- **Final completion:** 2021-12-07
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03996369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03996369, "Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03996369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*